More recently, the chemotherapy agent melphalan has been described as having efficacy and
the newer tyrosine kinase inhibitors (e.g. Palladia) may prove beneficial.
Not exact matches
Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the
tyrosine kinase inhibitor era, according to a
new study.
The breakthrough led to a
new type of cancer pharmaceutical, the
tyrosine kinase inhibitor.
The major drawback of
tyrosine kinase inhibitor therapy is the development of secondary resistance caused by the acquisition of
new mutations.
One of the main mechanisms of secondary resistance in patients treated with
tyrosine kinase inhibitors is acquisition of
new inhibitor - resistant mutations.